Diagnostic usefulness of dynamic changes of CMV-specific T-cell responses in predicting CMV infections in HCT recipients

Journal of Clinical Virology

Volumn 87, Issue , 2017, Pages 5-11

  Jung, Jiwon ^a,b   Lee, Hyun Jung ^a   Kim, Sun Mi ^a   Kang, Young Ah ^a   Lee, Young Shin ^a   Chong, Yong Pil ^a   Sung, Heungsup ^a   Lee, Sang Oh ^a   Choi, Sang Ho ^a   Kim, Yang Soo ^a   Woo, Jun Hee ^a   Lee, Jung Hee ^a   Lee, Je Hwan ^a   Lee, Kyoo Hyung ^a   Kim, Sung Han ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

Cytomegalovirus; ELISPOT; Hematopoietic stem cell transplantation

Indexed keywords

CYTOMEGALOVIRUS ANTIGEN PP65;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; APLASTIC ANEMIA; ARTICLE; CELLULAR IMMUNITY; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PREDICTIVE VALUE; PRIORITY JOURNAL; RECIPIENT; RELAPSE; SENSITIVITY AND SPECIFICITY; SEROLOGY; T LYMPHOCYTE; EVALUATION STUDY; IMMUNOLOGY; MIDDLE AGED; PROCEDURES;

ADULT; CYTOMEGALOVIRUS INFECTIONS; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNITY, CELLULAR; MALE; MIDDLE AGED; T-LYMPHOCYTES;

EID: 85004065569     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2016.11.012     Document Type: Article

References (15)

1. [1] Barron, M.A., Gao, D., Springer, K.L., Patterson, J.A., Brunvand, M.W., McSweeney, P.A., et al. Relationship of reconstituted adaptive and innate cytomegalovirus (CMV)-specific immune responses with CMV viremia in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 49 (2009), 1777–1783.
2. [2] Abate, D., Cesaro, S., Cofano, S., Fiscon, M., Saldan, A., Varotto, S., et al. Diagnostic utility of human cytomegalovirus-specific T-cell response monitoring in predicting viremia in pediatric allogeneic stem-cell transplant patients. Transplantation 93 (2012), 536–542.
3. [3] Kim, S.H., Lee, H.J., Kim, S.M., Jung, J.H., Shin, S., Kim, Y.H., et al. Diagnostic usefulness of cytomegalovirus (CMV)-Specific T cell immunity in predicting CMV infection after kidney transplantation: a pilot proof-of-concept study. Infect. Chemother. 47 (2015), 105–110.
4. [4] Kim, T., Lee, Y.M., Lee, S.O., Choi, S.H., Kim, Y.S., Woo, J.H., et al. Differences of cytomegalovirus diseases between kidney and hematopoietic stem cell transplant recipients during preemptive therapy. Korean J. Intern. Med. 31 (2016), 961–970.
5. [5] Ciaurriz, M., Zabalza, A., Beloki, L., Mansilla, C., Perez-Valderrama, E., Lachen, M., et al. The immune response to cytomegalovirus in allogeneic hematopoietic stem cell transplant recipients. Cell. Mol. Life Sci., 2015.
6. [6] Egli, A., Humar, A., Kumar, D., State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician. Clin. Infect. Dis. 55 (2012), 1678–1689.
7. [7] Reusser, P., Riddell, S.R., Meyers, J.D., Greenberg, P.D., Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 78 (1991), 1373–1380.
8. [8] Terrazzini, N., Kern, F., Cell-mediated immunity to human CMV infection: a brief overview. F1000Prime Rep., 6, 2014, 28.
9. [9] Quinnan, G.V. Jr., Kirmani, N., Esber, E., Saral, R., Manischewitz, J.F., Rogers, J.L., et al. HLA-restricted cytotoxic T lymphocyte and nonthymic cytotoxic lymphocyte responses to cytomegalovirus infection of bone marrow transplant recipients. J. Immunol. 126 (1981), 2036–2041.
10. [10] Quinnan, G.V. Jr., Kirmani, N., Rook, A.H., Manischewitz, J.F., Jackson, L., Moreschi, G., et al. Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N. Engl. J. Med. 307 (1982), 7–13.
11. [11] Mori, T., Okamoto, S., Matsuoka, S., Yajima, T., Wakui, M., Watanabe, R., et al. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant. 25 (2000), 765–769.
12. [12] Saldan, A., Forner, G., Mengoli, C., Gussetti, N., Palu, G., Abate, D., Strong cell-mediated immune response to human cytomegalovirus is associated with increased risk of fetal infection in primarily infected pregnant women. Clin. Infect. Dis. 61 (2015), 1228–1234.
13. [13] Forner, G., Saldan, A., Mengoli, C., Gussetti, N., Palu, G., Cytomegalovirus, Abate D., (CMV) enzyme-linked immunosorbent spot assay but not CMV QuantiFERON assay is a novel biomarker to determine risk of congenital CMV infection in pregnant women. J. Clin. Microbiol. 54 (2016), 2149–2154.
14. [14] Ohnishi, M., Sakurai, T., Heike, Y., Yamazaki, R., Kanda, Y., Takaue, Y., et al. Evaluation of cytomegalovirus-specific T-cell reconstitution in patients after various allogeneic haematopoietic stem cell transplantation using interferon-gamma-enzyme-linked immunospot and human leucocyte antigen tetramer assays with an immunodominant T-cell epitope. Br. J. Haematol. 131 (2005), 472–479.
15. [15] Nesher, L., Shah, D.P., Ariza-Heredia, E.J., Azzi, J.M., Siddiqui, H.K., Ghantoji, S.S., et al. Utility of the enzyme-linked immunospot interferon-gamma-release assay to predict the risk of cytomegalovirus infection in hematopoietic cell transplant recipients. J. Infect. Dis. 213 (2016), 1701–1707.